Comparison of the 2017 EULAR/ACR criteria with Bohan and Peter criteria for the classification of idiopathic inflammatory myopathies

Pinto, Benzeeta; Janardana, Ramya; Nadig, R.; Mahadevan, Anita; Bhatt, Anusha S; Raj, John Michael; Shobha, Vineeta

doi:10.1007/s10067-019-04512-6

Cited by 27 publications

(40 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Specificity was 88 % with a biopsy and 82 % without a biopsy. Sensitivity is therefore comparable with earlier classifications while specificity is superior [26]. Unfortunately, overlap myositis is not included as a subtype, and only one MSA (Anti-Jo-1 antibody) is currently included in the evaluation [5].…”

Section: Skin Signs Such As Heliotropic Erythemamentioning

confidence: 79%

Update on dermatomyositis in adults

Schlecht

Sunderkötter

Niehaus

et al. 2020

J Deutsche Derma Gesell

View full text Add to dashboard Cite

Dermatomyositis (DM) in adults has a prevalence of 6-7 per 100,000 population per year. This dedicated compact overview was prepared due to an increasing incidence as well as an often underestimated systemic involvement and new developments in myositis-specific antibodies (MSA). The spectrum of clinical dermatological and systemic symptoms is described. Related diagnostic procedures are depicted, and therapeutic regimens based on the German S2k guidelines and the current literature are presented. The urgency of an early diagnosis is emphasized as about 30 % of patients with DM manifest a tumor. Etiopathology is often associated with pulmonary fibrosis, and inflammation of myositis can cause irreversible muscle damage. Clinical signs and correct interpretation of serological markers can deliver valuable information on the extent of DM, and provide an indication for further diagnostic procedures, prognosis and choice of therapy.

show abstract

Section: Skin Signs Such As Heliotropic Erythemamentioning

confidence: 79%

Update on dermatomyositis in adults

Schlecht

Sunderkötter

Niehaus

et al. 2020

J Deutsche Derma Gesell

View full text Add to dashboard Cite

show abstract

“…This great variability clearly demonstrates the urgent need to harmonise methods, and that their clinical validation against the reference IP method remains an issue 8 9. In addition, studies conducted so far are retrospective, including patients diagnosed using previous criteria,11 and mostly performed on cohorts in which there was a very small number of some MSA, representing a further bias for comparative analysis 12 13. Nevertheless, today some tools have emerged that may help to improve the specificity of MSA detection by DIA/LIA and to confirm the diagnosis of MSA-associated IIM (table 1).…”

mentioning

confidence: 99%

Correspondence on ‘Standardisation of myositis-specific antibodies: where are we today?’

2019

View full text Add to dashboard Cite

“…Die Spezifität lag bei 88 % mit Biopsie und 82 % ohne Biopsie. Damit erreichen sie eine vergleichbare Sensitivität und bessere Spezifität als vorangegangene Klassifikationen . Leider ist die Overlap ‐Myositis nicht als Unterform enthalten, und außer dem Anti‐Jo‐1‐Ak wird bisher kein anderer MSA in der Wertung berücksichtigt .…”

Section: Labor‐ Und Apparative Diagnostikunclassified

Adulte Form der Dermatomyositis ‐ ein Update

Schlecht

Sunderkötter

Niehaus

et al. 2020

J Deutsche Derma Gesell

View full text Add to dashboard Cite

Die adulte Form der Dermatomyositis (DM) wird mit einer Prävalenz von 6-7 auf 100 000 Einwohner pro Jahr angegeben. Auf Grund der nachweislich steigenden Inzidenz, der häufig unterschätzen Systembeteiligung und neuer Entwicklungen zu den Myositis-spezifischen Antikörpern (MSA) wurde diese kompakte Übersicht zur Dermatomyositis erarbeitet. Des Weiteren wird das klinische Spektrum nicht nur dermatologischer Parameter, sondern auch organischer Symptome erläutert. Die diagnostische Aufarbeitung wie auch therapeutische Regime, basierend auf der S2k-Leitlinie und aktueller Literatur, werden präsentiert. Die Dringlichkeit einer frühen Diagnosestellung wird deutlich, zum einen da circa 30 % der DM-Fälle assoziiert Tumoren aufweisen, Verläufe oft mit Lungenfibrose vergesellschaftet sind und die Myositis zu irreversiblen Muskelschäden führt. Die klinischen Zeichen und eine korrekte Interpretation der serologischen Befunde geben wertvolle Hinweise für die Ausprägung der DM, die Indikationsstellung für weitergehende diagnostische Maßnahmen, die Prognose und Therapiewahl.

show abstract

Comparison of the 2017 EULAR/ACR criteria with Bohan and Peter criteria for the classification of idiopathic inflammatory myopathies

Cited by 27 publications

References 15 publications

Update on dermatomyositis in adults

Update on dermatomyositis in adults

Correspondence on ‘Standardisation of myositis-specific antibodies: where are we today?’

Adulte Form der Dermatomyositis ‐ ein Update

Contact Info

Product

Resources

About